Åpne denne publikasjonen i ny fane eller vindu >>Vise andre…
2026 (engelsk)Inngår i: VIEW, ISSN 2688-3988, artikkel-id 70180Artikkel i tidsskrift (Fagfellevurdert) Epub ahead of print
Abstract [en]
Lymphomas represent a biologically diverse group of B-, T-, and NK-cell malig-nancies, where challenges such as relapse, drug resistance, treatment-relatedtoxicity, sanctuary-site disease, and variable antigen expression continue toimpede therapeutic outcomes, despite significant advancements in immunother-apy. Nanomedicine presents a strategic approach to enhance drug delivery, targetmalignant lymphocytes or supportive microenvironmental cells, and integratemolecular imaging with therapy; however, the extent of clinical validation variesconsiderably across different platforms. This review provides an overview ofnanotechnology-enabled strategies for the treatment of lymphoma, includingantibody–drug and radioimmunoconjugates, liposomal and albumin-based drugcarriers, aptamer-guided systems, photothermal and photodynamic platforms,exosomes and liquid-biopsy nanoprobes, mRNA/lipid nanoparticle strategies,and AI-guided design. We highlight lymphoma-specific delivery challenges, suchas the presence of bulky nodal disease, circulating malignant cells, marrow andCNS involvement, splenic and hepatic sequestration, antigen sinks, and the lim-ited reliability of passive enhanced permeability and retention. Approved andguideline-supported examples are differentiated from active clinical trials and preclinical-only concepts to provide a clinically oriented interpretation of thecurrent evidence and future translational priorities.
sted, utgiver, år, opplag, sider
Australia: John Wiley & Sons, 2026
Emneord
B‑cell markers, CAR‑T, diagnostics, gene therapy, immunotherapy, lymphoma, nanocarrierdesign, nanomedicine, phototherapy, targeted drug delivery
HSV kategori
Forskningsprogram
nanopartiklar
Identifikatorer
urn:nbn:se:umu:diva-256935 (URN)10.1002/viw2.70180 (DOI)001822040700001 ()2-s2.0-105045128367 (Scopus ID)
Prosjekter
Cancer cachexia
Forskningsfinansiär
Cancerforskningsfonden i Norrland, AMP 25-1203
2026-07-292026-07-292026-07-30